Industry-Academia Partnerships: Designing the Future of Medicine

This Event has Passed

Where

Virtual

When

{{getUserDateTimezone("1708538400").singleDate}}
{{getUserDateTimezone("1708538400").time}} - {{getUserDateTimezone("1708542000").time}} {{getClientTimezoneName()}}

About

As scientific complexity increases, collaboration is critical to transforming cutting-edge thinking into approved therapies. How can academia and pharma be the best partners to each other in this fast-moving landscape? And how can they ensure their pioneering work reaches patients quickly? Join us as experts from both sides share best practices in agile development, nurturing scientific talent, and building strong foundations for innovation.

Moderator

Jesse McQuarters, Branded Content Editor at STAT

Speakers

Calum MacRae, M.D., Ph.D., Vice Chair, Brigham and Women’s Hospital

Calum is a basic and translational scientist who works at the interface between biology and technology. He is a Professor at Harvard Medical School, Principal Faculty Member at the Harvard Stem Cell Institute and an Associate Member of the Broad Institute of Harvard and MIT. His major clinical focus is the genetic basis of chronic medical disorders and the early identification of preventable disease.

Andrew Mortlock, Ph.D., Head of Early Development, Astellas Pharma

With more than 25 years of experience in biopharma, Andrew is focused on accelerating an exciting pipeline of modalities, including small molecules, antibodies, and cell and gene therapies. A pre-clinical scientist by training, he is passionate about taking compounds from research to registration to advance tomorrow’s medicines.

Tadaaki Taniguchi, M.D., Ph.D., Chief Medical Officer, Astellas Pharma

With a career in biopharma spanning 20 years, Tadaaki is driven by focusing on the best science and empowering the best talent to pursue it. An internationally trained surgeon in the field of oncology, he has extensive industry experience in developing and commercializing innovative medicines.